Vectivbio Ag Is A Clinical Stage Biotechnology Company Based In Baselswitzerlandfounded In May 2019The Company Is Focused On Developing Innovative Treatments For Severe Rare Conditionsparticularly Those Affecting The Gastrointestinal Systemvectivbio Aims To Address Significant Unmet Medical Needs By Targeting Diseases With Well Defined Biology The Lead Product Candidate From Vectivbio Is Apraglutidea Long Acting Synthetic Glp 2 Analogthis Therapy Is Being Developed For Conditions Such As Short Bowel Syndrome With Intestinal Failure And Acute Graft Versus Host Diseasethese Conditions Present Considerable Challengesand Vectivbio Is Committed To Improving Patient Outcomes Through Effective Treatmentsthe Company Is Also In The Process Of Being Acquired By Ironwood Pharmaceuticalsemphasizing The Strategic Importance Of Its Therapeutic Pipeline
No conferences found for this company.
| Company Name | Vectivbio Ag |
| Country |
Switzerland
|
| Address | N/A |
| Telephone | N/A |
| N/A |
